Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

In this: publication
By this: publisher
In this Subject: <a title="Medicine (General)" href="/content/subcat?j_subject=205&j_availability=">Medicine (General)
By this author: Currie, Craig J. ;&nbsp; McEwan, Phil ;&nbsp; Poole, Chris ;&nbsp; Valentine, William J. ;&nbsp; Palmer, Andrew J. ;&nbsp; Lammert, Morten ;&nbsp; Nicklasson, Lars ;&nbsp; Foos, Volker ;&nbsp; Roze, St&#233;phane

Authors: Currie, Craig J.¹; McEwan, Phil²; Poole, Chris³; Valentine, William J.⁴; Palmer, Andrew J.⁴; Lammert, Morten⁵; Nicklasson, Lars⁶; Foos, Volker⁴; Roze, Stéphane⁴

Source: Current Medical Research and Opinion, Volume 22, Number 5, May 2006 , pp. 967-969(3)

Publisher: Informa Healthcare

Buy & download fulltext article:

Price: $51.50 plus tax (Refund Policy)

Document Type: Letter section

DOI: http://dx.doi.org/10.1185/030079906X00000

Affiliations: 1: Honorary Senior Research Fellow, Diabetes, Endocrinology and Metabolism, School of Medicine, Cardiff University, UK 2: Lecturer in Computational Statistics, School of Mathematics, Cardiff University, UK 3: Senior Research Pharmacist, Cardiff, UK 4: ORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland 5: Novo Nordisk A/S, Bagsvaerd, Denmark 6: Novo Nordisk Inc., Princeton, NJ, USA